Figure 1.
Mean concentration-time profile for udenafil (a) and DA-8164 (b) following oral administration of 37.5, 87.5, and 125 mg daily, and 37.5 and 87.5 mg twice daily. For twice daily dosing, the second twelve hours is imputed from the first twelve hours.